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Background: The use of tumour xenografts is a well-established research tool in cancer genomics but has not yet
been comprehensively evaluated for cancer epigenomics.
Methods: In this study, we assessed the suitability of patient-derived tumour xenografts (PDXs) for methylome analysis
using Infinium 450 K Beadchips and MeDIP-seq.
Results: Controlled for confounding host (mouse) sequences, comparison of primary PDXs and matching patient
tumours in a rare (osteosarcoma) and common (colon) cancer revealed that an average 2.7% of the assayed CpG sites
undergo major (Δβ≥ 0.51) methylation changes in a cancer-specific manner as a result of the xenografting procedure.
No significant subsequent methylation changes were observed after a second round of xenografting between primary
and secondary PDXs. Based on computational simulation using publically available methylation data, we additionally
show that future studies comparing two groups of PDXs should use 15 or more samples in each group to minimise
the impact of xenografting-associated changes in methylation on comparison results.
Conclusions: Our results from rare and common cancers indicate that PDXs are a suitable discovery tool for cancer
epigenomics and we provide guidance on how to overcome the observed limitations.Background
Xenografting of human tumours into mice or rats has
been performed since the late 1960s [1], but it was not
until the advent of immunodeficient mouse strains (for
example, severe combined immunodeficiency (SCID) mice)
in the mid-1980s that the practice became widespread
in basic research and preclinical studies [2]. These new
models of disease brought with them new hopes of
therapeutic advances but have also displayed a number
of noteworthy limitations [2]. Firstly, both the surrounding
stroma and the blood vessels recruited to the growing
tumour during angiogenesis effectively incorporate mur-
ine cells into the transplanted tumour. Secondly, placing
the xenograft orthotopically is technically challenging,
so most are grown subcutaneously, effectively eliminating
the possibility of replicating metastatic disease. Despite
these limitations, patient-derived tumour xenografts (PDXs)* Correspondence: s.beck@ucl.ac.uk
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unless otherwise stated.have proven extremely accurate at predicting drug response
in various cancer types [3], and have been used in numer-
ous preclinical studies [4].
Osteosarcoma (OS) is the most common form of pri-
mary bone cancer, yet remains incredibly rare with an
age-standardised incidence in the UK of 8 and 6 per
million in males and females, respectively [5]. Thus, one
of the major issues with the study of rare cancers such
as OS is the scarcity of primary samples to analyse. This
highlights the need for an accurate model of the disease
and PDXs have been shown in multiple cancer types to
better represent the genetic and gene-expression char-
acteristics of tumours than in vitro cell lines [6]. More-
over, because OS presents most often in adolescents
and young adults, who are less likely to enrol into clin-
ical trials [7], patient recruitment can often take several
years, thus enhancing the inherent jeopardy in drug selec-
tion for these trials. With this in mind, in vivo tumour
models that most accurately replicate the patient’s condi-
tion are a crucial factor in experimental pharmacology.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in preclinical research [8], and OncoTrack, the largest
European public-private biomarker consortium which
aims to develop novel biomarkers for targeted therapy
[9], generated PDXs that were included here as an add-
itional tumour type and an example of a common cancer
(colon cancer (CC)). Despite the popularity of PDXs, only
a few systematic studies have compared their fidelity to
the original tumours from which they were derived. None-
theless, the findings have been encouraging: in pancreatic
cancer, for instance, gene expression patterns were faith-
fully retained in PDXs and the majority of the observed
changes were associated with pathways reflecting the
microenvironment [10], and in breast cancer less than
5% of genes showed variation in expression between
PDXs and the corresponding primary tumour [11]. To
our knowledge, however, only one systematic genomic
profiling of patient tumours and PDXs is available in the
literature: it shows that all copy number variants are
maintained in PDXs, and that while xenografts do ini-
tially present a small number of single nucleotide vari-
ants (approximately 4,300), the vast majority of changes
that accumulate over time occur in non-coding parts of
the genome [12]. Similarly, only one study has assessed
genome-wide DNA methylation changes in head and
neck squamous cell carcinomas using the earlier Infi-
nium 27 K BeadChip, and found no statistically signifi-
cant changes [13].
To address this gap in our current knowledge, we have
carried out a comprehensive assessment of the suitability
of PDXs for cancer epigenomics. The assessment included
methylome analysis using array- and sequencing-based
technologies of primary and secondary PDXs derived from
rare (OS) and common (CC) cancers as well as computa-
tional simulations.
Methods
Tumour samples and xenografting
The research described below conformed to the Helsinki
Declaration.
For OS, PDXs were generated from tumour samples
obtained from the Stanmore Musculoskeletal Biobank,
satellite to the UCL Biobank for Health and Disease.
Ethical approval for the OS samples was obtained from the
Cambridgeshire 2 Research Ethics Service, UK (reference
09/H0308/165), and the UCL Biobank for Health and
Disease, which is held under the Human Tissue Author-
ity licence 12055: project EC17.1. Samples were washed
in phosphate-buffered saline and cut to the appropriate
size (approximately 2 to 3 mm3). Under isoflurane an-
aesthesia delivered via a nasal attachment tube, tumour
fragments were inserted subcutaneously in one or both
flanks of the mice. In total, 14 female SCID mice (3 to 6
weeks old) were kept at the UCL Animal Housingfacility in individually ventilated cages, and monitored
at least twice a week for the duration of the experiment.
Procedures were followed as described in the project li-
cense (delivered by the UK Home Office PPL 70/6666)
and, when necessary, animals were sacrificed according
to an approved schedule 1 protocol. Tumour growth was
measured using digital measuring callipers. Tumours were
snap-frozen in liquid nitrogen after excision.
For CC, PDXs were generated from tumour tissue de-
rived from surgical specimens of patients with colorectal
cancer. The tissue samples and respective data from the
Medical University of Graz were provided by the Bio-
bank Graz with Ethics approval of the project under the
ethical commission number 23-015 ex 10/11. The tissue
samples and data from the Charite Medical University in
Berlin were provided with Ethics approval EA1/069/11.
The tumour samples were received directly from the
hospitals in Berlin (Charité) and Graz (Medizinisches
Universitätsklinikum) under sterile conditions. The tu-
mours were cut into 2 × 2 mm fragments and placed in
a sterile Petri dish covered with HANKs balanced salt
solution. Mice were anaesthetised by a single intraven-
ous injection (0.15 ml/mouse) with Etomidate-®Lipuro
(0.3 mg/mouse) and each fragment was inserted subcuta-
neously into the left flank of the recipient mouse. We used
immune deficient female NMRI nu/nu mice, supplied
from Taconic (Lille Skensved, Denmark) or Charles River
(Sulzfeld, Germany). The mice were kept at EPO under
sterile conditions in strictly controlled and standardised
barrier conditions, IVC System Tecniplast DCC (Tecni-
plast Deutschland GmbH, Hohenpeißenberg, Germany).
The body weight and health of the mice were controlled
throughout the experiment. After the xenotransplantation,
tumour growth was monitored at least twice a week using
callipers. Mice were sacrificed when the tumours reached
a volume of ≥1,000 mm3 or when the animals lost ≥20%
body weight.DNA methylation analysis
Genomic DNA was extracted from PDX samples using
the QIAamp DNA Mini Kit (Qiagen, Venlo, Limburg,
Netherlands) according to the manufacturer’s instructions,
and subjected to methylation analysis. The bisulphite con-
version of the DNA was performed using the EZ DNA
Methylation kit (Zymo Research, Irvine, California, USA)
on 500 ng. Conversion efficiency was assessed by quantita-
tive PCR. The Illumina Infinium HumanMethylation450
BeadChips were processed as per the manufacturer’s in-
structions. The MeDIP-seq libraries were prepared as pre-
viously described [14] and sequenced on a HiSeq 2000.
The resulting 450 K and MeDIP-seq data were deposited
into the Gene Expression Omnibus as a SuperSeries under
accession number GSE59352.
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The raw data obtained from the 450 K arrays were proc-
essed from the IDAT files through to normalisation with
BMIQ [15] using the ChAMP [16] pipeline, and all subse-
quent analysis was performed with the R statistical soft-
ware v3.0.2 and custom scripts. Quality control of the
array data included removal of probes for which any sam-
ple did not pass a 0.01 detection P-value threshold, bead
cutoff of 0.05, and removal of probes on the sex chromo-
somes. Probes passing the detection P-value threshold of
0.01 in the mouse-only sample were also removed from
downstream analysis in all xenografts to avoid confound-
ing signal from any mouse DNA. The genomic and epige-
nomic features used are those annotated on the array and
enrichments were calculated on the basis of 1,000 repeti-
tions of a random selection of probes from the overall
probe set used in the analysis.
The sequencing data were processed from fastq files
using the MeDUSA [17] pipeline. The reads were aligned
separately to both the hg19 and mm10 genomes, with all
redundant and unpaired reads removed. After assessment
of the levels of likely contamination from mouse DNA as
well as based on recommendations from other studies
[18], those reads aligning only to human or to both hu-
man and mouse were kept for downstream analysis.
Results and discussion
Comparison of osteosarcoma PDXs and patient tumours
To investigate the methylation changes linked to deriv-
ing xenografts from patient tumours, we subcutaneously
inserted OS fragments from two patients in the flanks of
SCID mice, and grew them over two generations accord-
ing to the scheme described in Figure 1.T2P
T1P
Mouse 3
Mouse 1
Mouse 2
T2X1
T1X1
T1X2A
T1X2B
Patient Osteosarcoma 
Tumours
1st Generation X
Figure 1 Osteosarcoma PDX derivation scheme. A single fragment from
subcutaneously into each flank of a SCID mouse. Patient tumour 1 (T1P) ga
PDXs, while patient tumour 2 (T2P) was used to produce one PDX at eachA final sample set consisting of two patient tumours
(T1P and T2P), four first generation PDXs, and three
second generation PDXs were available for methylation
analysis on the Illumina Infinium 450 K Beadchips [19].
A major concern with analyses of human tumours grown
in mice is the potential for signal contamination by host
DNA from tumour vascularisation during its development
or from the surrounding stroma when extracting the
tumour. In order to eliminate these confounders in our
methylation analysis, an additional mouse kidney sample
was processed on the 450 K array and the 45,934 probes
passing a detection P-value threshold of 0.01 were removed
from downstream analysis. The use of the detection P-value
ensured that probes were filtered out based solely on their
ability to hybridise to the sample DNA as opposed to their
methylation status. This makes the mouse kidney sample
an appropriate tissue for filtering probes in the analysis of
both types of cancers described in this study. The raw data
for all samples were subsequently processed through the
ChAMP analysis pipeline [16] (see Methods) to produce a
final dataset of 9 samples and 463,558 probes.
The distributions of methylation at the genome-wide
and feature-specific levels for each sample are shown in
Figure 2. Although methylation levels appear remarkably
consistent within each tumour set, and in line with ex-
pected feature-specific values (for example, low methylation
at CpG islands), there is a slight increase in methylation
levels across all features between the two patient tumours
and their derivatives.
Specifically assessing methylation differences at each
probe between a PDX and its original patient tumour fur-
ther supports the maintenance of most of the methylome
in tumour xenografts: Figure 3a shows that only a smallMouse 6
Mouse 5
T2X1X1
T1X2BX1
Mouse 4 T1X2AX1
enografts 2nd Generation Xenografts
each patient tumour, approximately 1 mm in diameter, was inserted
ve rise to three first generation PDXs and two second generation
generation.
Figure 2 DNA methylation distribution by feature. For each feature, in each sample, the β-values are binned into 1% methylation increments
(described by the colour scale), and the percentage of probes at each methylation level is shown in the individual plots. The top and bottom
eight plots correspond to the T1 and T2 sets, respectively. Whole Genome = all probes. IGR, intergenic region; TSS, transcription start site.
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methylation. We have previously shown [20] that 95% of
fully unmethylated probes display β-values ≤0.31, while
fully methylated probes have β-values ≥0.82; thus a Δβ
threshold of 0.51 can be used as the minimum change ex-
pected for a CpG to be observed as going from fully
unmethylated to methylated or vice versa ('reversed
methylation'). Using this threshold in the comparisons of
PDXs and patient tumours, as shown in Figure 3b, an
average of only 0.85% of probes in the T1 set (n = 5) and
6.35% in the T2 set (n = 2) are measured as reversing their
methylation status, leading to inaccurate results if using
the PDX as a proxy for the patient tumour.
Comparison of osteosarcoma PDXs across generations
Interestingly, although each set of PDXs displays this shift
with xenografting, a constant profile is then maintainedwithin a xenograft lineage: T1X2A, T1X2B and their sec-
ond generation tumours all displayed consistent levels
across features (Figure 2), as did T2X1 and T2X1X1, dem-
onstrating that although the change in host is linked to a
slight increase in methylation levels, subsequent xeno-
grafting is not accompanied by additional changes. This is
confirmed by the vastly reduced number of reversed
methylation events observed between first and second
generation PDXs as opposed to those identified within the
first generation; Figure 3 reveals that an average of only
0.07% (n = 3) of CpG sites see their methylation scores in-
crease or decrease by over 0.51 after the first generation.
This result suggests either an initial reaction to the new
host that is then preserved in further generations as the
mice used were isogenic, or a loss of tumour heterogeneity
as only a fragment of the initial patient sample was used
for xenografting, or a combination of these two factors.
ab
Figure 3 Assessment of methylation changes in OS PDXs. (a) For each PDX, the absolute difference (βPatient - βXenograft) is calculated at each
probe and binned into 1% methylation difference increments (described by the colour scale); the percentage of probes showing each methylation
difference level is shown in the individual plots. (b) Number and percentage of probes in each comparison changing by 0.51 or more, corresponding
to all probes going from fully unmethylated to fully methylated and vice versa.
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persist in further generations as only a fragment of the
grown tumour is transplanted at each passage, and that
signal from new host stromal cells and vascularisation
affect gene expression in specific pathways (such as extra-
cellular matrix formation) [10] suggests that the observed
epigenetic change is due primarily to implantation of the
tumour into a new host.
Validation with MeDIP-seq
In addition to the methylation arrays, the OS PDXs and
patient samples were analysed by methylated DNA immu-
noprecipitation followed by low-coverage next-generation
sequencing (MeDIP-seq) [21]. Alignment, filtering of reads,
and calling of differentially methylated regions (DMRs)
were performed using the MeDUSA pipeline [17]. In
order to minimise read contamination by mouse DNA,
the fastq files were aligned separately to the human and
mouse genomes and those reads aligning only to mousewere removed from downstream analysis. With our data
this approach yielded a nearly identical final read set as
using the Xenome [18] protocol, designed specifically for
xenograft sequencing data, with over 98% overlap in each
sample. Final read counts aligning to human, mouse or
both are shown in Additional file 1.
The MeDIP-seq DMRs identified across all seven pa-
tient tumour/xenograft comparisons overlapped with 48
probes present on the 450 K array; importantly, the direc-
tionality of methylation change between patient tumour
and xenograft was 100% concordant between the two
methods, with the same 22 gains and 26 losses of methyla-
tion identified in the PDXs.
Similarly, in an inter-tumour comparison, when asses-
sing the ability of a PDX to substitute for its matched
patient tumour in an inter-tumour comparison (that is,
T1P versus T2P), 450K and MeDIP-seq both identified
similar trends (Figure 4): for each technology, the differ-
ences between the patient tumours T1P and T2P were
a b
Figure 4 PDXs as substitutes for patient tumours: 450 K versus MeDIP-seq. (a) The absolute difference in β-value between the two OS
patient tumours is calculated at each probe. The absolute difference between each PDX and the patient tumour from the other tumour set is
then assessed, and a ΔΔβ for those two differences is calculated and plotted as in Figure 3. A result close to zero indicates concordance between
the two measurements at a given CpG site. (b) Similarly to the process described above with the 450 K array, the number of DMRs between the
two patient tumours that can be recapitulated between a PDX and the patient tumour are shown, for both hyper- and hypo-DMRs.
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compared with the unmatched patient to see if the same
differential methylation was captured. MeDIP-seq showed
similar levels of concordance in the comparisons as the
methylation array, with the exception of two of the hypo-
methylation sets (T1PvT2X1 and T1PvT2X1X1) that dis-
played lower levels of concordance (22.4% and 17.6%,
respectively) in the MeDIP-seq data (Figure 4b). These,
however, represent only small absolute differences in con-
cordance (66 and 70 DMRs of the T1P versus T2P com-
parison were not identified in T1P versus T2X1 and T1P
versus T2X1X1, respectively) due to the overall low num-
ber of hypomethylated DMRs detected between the two
patient tumours (n = 85) compared with hypermethylated
(n = 1,980).
Methylome changes in colon cancer and osteosarcoma
PDXs
In order to further investigate those few CpG sites with
changing methylation levels after xenografting, an add-
itional set of six patient tumour/xenograft CC pairs fromthe OncoTrack consortium were assessed using Illumina
450K arrays and processed with the R package ChAMP.
Grouping these with the first generation PDXs derived
from OS tumours yields a final cohort of 10 sample pairs
(Figure 5). Using the same Δβ threshold of 0.51 as for the
OS samples, a similarly low number of probes were identi-
fied as changing with xenografting in the first generation,
with an average of 3.18% (n = 6). Of note, when using
lower Δβ thresholds, the average percentage of probes
changing with xenografting increases to a maximum of
18% (Figure 5c).
To assess whether changes in methylation could be gen-
eralised to any tumour undergoing this procedure or
whether they are tumour or tumour type-specific, the
overlap in these changing probes within as well as be-
tween tumour types was evaluated. Statistically significant
overlaps were found within each tumour type, with 236
probes changing in all first generation OS PDXs and five
probes in CC PDXs (random resampling P-value <10-4);
however, gene ontology tools (GREAT [22], Panther [23],
DAVID [24]) did not reveal any particular functional links
ab
c
Figure 5 Assessment of methylation changes in OS and CC PDXs. (a) For each PDX, at each probe, the absolute difference (βPatient - βXeno-
graft) is calculated and binned into 1% methylation difference increments (described by the colour scale); the percentage of probes showing each
methylation difference level is shown in the individual plots. (b) Number and percentage of probes in each comparison changing by 0.51 or
more, corresponding to all probes going from fully unmethylated to fully methylated and vice versa. (c) The mean percentage of changing
probes across all samples at thresholds of 0.51, 0.41, 0.31, and 0.21. Error bars correspond to the standard error of the mean.
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between the two tumour types. This suggests that the
changes in methylation observed with xenografting are
unlikely to be due to a systematic reaction to the xeno-
grafting procedure but rather point to tumour specificity.
Finally, we assessed whether these methylation changes
were more likely to occur in certain genomic and/or
epigenomic features. As shown in Figure 6, these probes
are depleted for promoter regions and CpG islands, but
enriched for intergenic regions, particularly those with
low CpG density (P-value <10-4).
In the OS cohort, one of the patient tumours produced
three first-generation PDXs, grown in two animals. Two
of the PDXs (T1X2A and T1X2B) were harvested from
the same mouse, one from each of the flanks. Despite the
limited sample size, this set-up provides novel and import-
ant insights into the potential tumour specificity of the
observed changes in methylation. The results displayed
in Figure 7 reveal that over 86% of probes changing in
T1X2B also underwent major changes in T1X2A, andover 64% of changes were common between all three
PDXs originating from T1P. These overlaps, much higher
than those observed within or across tumour types, fur-
ther confirm tumour specificity of the observed methyla-
tion changes that accompany xenografting.
Practical implications for the use of PDXs in epigenetic
studies
With a mean percentage of 2.7% (n = 11,110) of CpG
sites undergoing major methylation shifts in first gener-
ation xenografts, PDXs appear to be more than adequate
proxies for patient samples in methylation studies, as
compared, for example, with the 0.27 to 0.72 correlation
reported between whole blood and Epstein-Barr virus-
transformed lymphocyte cell lines [25]. These are com-
monly used proxies in genetic studies, and have been
previously used in associating methylation patterns with
phenotypes [26]. However, the tumour-specific nature of
these methylation changes implies that no accurate pre-
diction as to which 2.7% of the measured methylation
%
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Figure 6 Enrichment of (epi)genomic regions with changing methylation status after xenografting. Each probe on the 450 K array is annotated
to a genomic (TSS1500, Body, 3′ UTR…) and epigenomic (island, shore, shelf, none) region. These were combined for each probe to form a unique
(epi)genomic annotation and enrichments were calculated using a random resampling strategy. IGR, intergenic region; TSS, transcription start site.
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general statement concerning enrichment in intergenic
regions. In order to aid in the design of future studies,
we devised a model to test how many 450K arrays
should be run when comparing two groups of samples
in order to minimise the effects of these tumour-specific
xenografting-linked methylation changes. From a total of
2,000 data sets from Marmal-aid [27], a 450K data re-
pository, we selected n (5 ≤ n ≤ 50) samples. These were
taken at random from the tissue and disease types avail-
able to avoid any bias that might be introduced due to
higher levels of similarity between the methylomes of sam-
ples from a particular tissue type compared with another.Figure 7 Overlap of changing CpG sites between PDXs originating fro
T1P in two flanks of the same mouse. T1X1 was grown from T1P in a differ
number of changing sites in T1X2B, the PDX with the fewest changes. Ove
T1X2A, and over 64% of changes were common between all three PDXs oThis ensures the resulting model can be used regardless of
tissue origin. A total of 11,110 β-values in each sample
were then increased or decreased by 0.51 (5,555 of each).
We subsequently compared the original n samples from
Marmal-aid with their modified counterparts and assessed
the number of sites that appeared to be significantly
differentially methylated between the groups (Figure 8),
as determined by a Wilcoxon rank-sum test with a non-
adjusted P-value threshold of 0.05. The non-adjustment for
multiple testing allows flexibility in future study design, such
as investigations using only a subset of the array.
This analysis revealed that the maximum number of
probes significantly differentially methylated between them the same patient tumour. T1X2A and T1X2B were grown from
ent animal. Overlap percentages were calculated based on the
r 86% of probes changing in T1X2B also underwent major changes in
riginating from T1P.
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Figure 8 Model of the effect of PDX-associated methylation changes. For sample numbers n from 5 to 50, n random samples were
randomly selected from 2,000 Marmal-aid data sets. Each sample was modified at 11,110 probes by β = 0.51 and a Wilcoxon rank-sum test run
between the original n samples and the modified versions. The number of significantly differentially methylated probes (P-value ≤0.05) for each
n is plotted against n. The model was run five times and the error bars represent the standard error of the mean at each n.
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the xenografting-associated methylation changes will
only significantly affect the differences between groups
at two loci on average. This further demonstrates the
suitability of tumour xenografts for methylome analysis.
It is noteworthy that although using more than 15 sam-
ples in each cohort will continue to reduce the effect of
xenografting-associated methylation changes on group
methylation characteristics, the benefits in terms of af-
fected probes will be substantially less than with the first
15 samples, as shown in Figure 8.
Conclusions
This work advances our understanding of the epigenetic
dynamics involved in PDX and provides guidance on the
utility and interpretation of PDX-derived DNA methyla-
tion data. Our results from both rare (OS) and common
(CC) cancer types show that less than 3% of the 450 K
methylome undergoes major changes with xenografting.
Moreover, these changes appear to be cancer-specific
and little to no further methylation changes are observed
in secondary xenografts. Finally, we propose a model to
aid the design of future studies and minimise the impact
of xenografting-associated confounding of DNA methy-
lation in the interpretation of PDX-based studies.Additional file
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